Eleva Capital’s Aquestive Therapeutics AQST Stock Holding History

Eleva Capital’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.3K	Hold	2,720	–	–	﹤0.01%	24
2026 Q1	$11.3K	Buy	+2,720	New	+$11K	﹤0.01%	24

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Eleva Capital's AQST Position: Q2 2026 in Review

Eleva Capital held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 2,720 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #24.

Eleva Capital first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Eleva Capital held 2,720 shares of Aquestive Therapeutics worth $11.3K as of Q2 2026.
Eleva Capital left its Aquestive Therapeutics share count unchanged in Q2 2026.
Aquestive Therapeutics made up ﹤0.01% of Eleva Capital's portfolio in Q2 2026, its #24 holding.
Eleva Capital first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Eleva Capital's 13F filing for Q2 2026, filed 2 Jul 2026.